International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial

Publisher： John Wiley & Sons Inc

E-ISSN： 1600-6143|15|4|1091-1100

ISSN： 1600-6135

Source： AMERICAN JOURNAL OF TRANSPLANTATION, Vol.15, Iss.4, 2015-04, pp. : 1091-1100

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Successful Treatment of EBV PTLD with CNS Lymphomas with the Monoclonal Anti-CD20 Antibody Rituximab

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 691-693

Karger

Access to resources Recommend Favorite

Rituximab for PTLD of the CNS: Is It a ‘No-Brainer’?

By  

Oncology Research and Treatment, Vol. 31, Iss. 12, 2008-11 ,pp. : 650-651

Karger

Access to resources Recommend Favorite

Recursive partitioning analysis of prognostic factors in post‐transplant lymphoproliferative disorders (PTLD): a 120 case single institution series

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 4, 2015-11 ,pp. : 491-500

John Wiley & Sons Inc

Access to resources Recommend Favorite

Managing the challenge of PTLD in liver and bowel transplant recipients

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 169, Iss. 2, 2015-04 ,pp. : 157-172

John Wiley & Sons Inc

Access to resources Recommend Favorite

Obinutuzumab (GA101) for the Treatment of Chronic Lymphocytic Leukemia and Other B-Cell Non-Hodgkin's Lymphomas: A Glycoengineered Type II CD20 Antibody

By  

Oncology Research and Treatment, Vol. 38, Iss. 4, 2015-03 ,pp. : 185-192

Karger

Access to resources Recommend Favorite